CBD has been reported to inhibit angiogenesis related to the proliferation of estrogen receptor-positive breast cancer [3] by inactivating proangiogenic factors such as vascular endothelial growth factor (VEGF), integins or angiopoietins, matrix metalloproteinase-2/9 (MMP-2/9), the urokinase-type plasminogen activator (uPA), endothelin-1 (ET-1), and platelet-derived growth factor-AA (PDGF-AA), or by activating inhibitory effectors such as thrombospondins or interferons [4,5,6]. The gene discussed is PLAU; the disease is breast cancer.